- Home
- BFRG vs VYNE Comparison
BFRG vs VYNE Comparison
Compare BFRG & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BFRG | VYNE |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1M | 12.5M |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BFRG | VYNE |
|---|---|---|
| Price | $1.00 | $0.62 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 65.3K | ★ 904.6K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $116,670.00 | ★ $524,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.29 |
| 52 Week Low | $0.80 | $0.28 |
| 52 Week High | $4.84 | $4.30 |
Technical Indicators
Market Signals| Indicator | BFRG | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 41.06 | 80.27 |
| Support Level | $1.10 | $0.35 |
| Resistance Level | $1.21 | $0.42 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 13.97 | 66.52 |
Price Performance
Historical ComparisonAbout BFRG Bullfrog AI Holdings Inc.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.